NCT04965688
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment with anastrozole or letrozole and a CDK4/6 inhibitor; Patients who have not had progression while on or within 6 months of stopping the CDK4/6 inhibitor; Patients with prior treatment within 2 years with fulvestrant, alpelisib, everolimus, or capecitabine
https://ClinicalTrials.gov/show/NCT04965688